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Investigating Molecular Mechanisms Underlying Mild Phenotype In Friedreich
Ataxia Patients With G130v Missense Mutation
Abstract
Friedreich’s Ataxia (FRDA) is an incurable neurodegenerative disease caused by mutations in the frataxin
(FXN) gene, resulting in decreased expression of the mitochondrial protein FXN. 2-3% of FRDA patients
carry a GAA expansion on one FXN allele, and a missense mutation on the other. The mechanism behind
the disease‐causing features remains elusive. The phenotype associated with patients carrying point
mutations cannot be predicted with certainty; these patients can have a mild or severe clinical outcome,
creating a unique platform to understand clinical heterogeneity. FXN is important for proper mitochondrial
function, and is involved in Fe-S cluster biogenesis, metabolism, and ATP production. Defining how
missense mutations influence FXN’s processing and role in energy production and cellular metabolism
will help identify pathways that are affected during disease progression, begin to explain the varying
phenotypes, and establish a biochemical genotype-phenotype correlation. Of all disease-associated
mutations, patients carrying the G130V missense mutation are of most interest because they have less
than 5 % of control mature FXN levels but evolve to a milder phenotype with slower disease progression
and significantly lower occurrence of cardiomyopathy, scoliosis, and diabetes. In this thesis, I identified
impaired protein processing from FXN42-210 to FXN81-210 as the mechanism by which FXN missense
mutations result in lower mature FXN81-210 levels in mutation-selective ways by overexpression studies
and subcellular fractionation. This was also true for a novel FXN W168R missense mutation associated
with severely low FXN levels and phenotype. Multiple features of mitochondrial dysfunction associated
with severe phenotype in typical FRDA, and compared them to G130V patients were also assessed in
order to understand the molecular mechanisms underlying the milder phenotype. Fibroblasts from G130V
patients have increased mitochondrial ferritin immunoreactivity by immunocytochemistry, increased
mitochondrial aconitase activity measured by enzymatic conversion of citrate to isocitrate, and increased
Krebs cycle metabolic activity measured by LC-MS isotopologue tracer studies, compared to typical FRDA
fibroblasts. Overall, fibroblasts from G130V patients appear to have improved mitochondrial function
compared to typical FRDA patients, thus providing a rationale linking G130V functional capacity with
milder phenotype.
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ABSTRACT
INVESTIGATING MOLECULAR MECHANISMS UNDERLYING MILD PHENOTYPE IN
FRIEDREICH ATAXIA PATIENTS WITH G130V MISSENSE MUTATION

Elisia M. Clark

David R. Lynch MD, PhD

Friedreich’s Ataxia (FRDA) is an incurable neurodegenerative disease caused by
mutations in the frataxin (FXN) gene, resulting in decreased expression of the
mitochondrial protein FXN. 2-3% of FRDA patients carry a GAA expansion on one FXN
allele, and a missense mutation on the other. The mechanism behind the
disease-causing features remains elusive. The phenotype associated with patients
carrying point mutations cannot be predicted with certainty; these patients can have a
mild or severe clinical outcome, creating a unique platform to understand clinical
heterogeneity. FXN is important for proper mitochondrial function, and is involved in FeS cluster biogenesis, metabolism, and ATP production. Defining how missense
mutations influence FXN’s processing and role in energy production and cellular
metabolism will help identify pathways that are affected during disease progression,
begin to explain the varying phenotypes, and establish a biochemical genotypephenotype correlation. Of all disease-associated mutations, patients carrying the G130V
missense mutation are of most interest because they have less than 5 % of control
mature FXN levels but evolve to a milder phenotype with slower disease progression
and significantly lower occurrence of cardiomyopathy, scoliosis, and diabetes. In this
vi

thesis, I identified impaired protein processing from FXN42-210 to FXN81-210 as the
mechanism by which FXN missense mutations result in lower mature FXN81-210 levels in
mutation-selective ways by overexpression studies and subcellular fractionation. This
was also true for a novel FXN W168R missense mutation associated with severely low
FXN levels and phenotype. Multiple features of mitochondrial dysfunction associated
with severe phenotype in typical FRDA, and compared them to G130V patients were
also assessed in order to understand the molecular mechanisms underlying the milder
phenotype. Fibroblasts from G130V patients have increased mitochondrial ferritin
immunoreactivity by immunocytochemistry, increased mitochondrial aconitase activity
measured by enzymatic conversion of citrate to isocitrate, and increased Krebs cycle
metabolic activity measured by LC-MS isotopologue tracer studies, compared to typical
FRDA fibroblasts. Overall, fibroblasts from G130V patients appear to have improved
mitochondrial function compared to typical FRDA patients, thus providing a rationale
linking G130V functional capacity with milder phenotype.

vii

TABLE OF CONTENTS

DEDICATION ....................................................................................................... III
ABSTRACT ..........................................................................................................VI
TABLE OF CONTENTS ..................................................................................... VIII
LIST OF TABLES .................................................................................................IX
LIST OF FIGURES ................................................................................................X
ABBREVIATIONS ...............................................................................................XII
CHAPTER 1: INTRODUCTION TO FRIEDREICH ATAXIA .................................. 1
CHAPTER 2: SELECTED MISSENSE MUTATIONS IMPAIR FXN
PROCESSING .................................................................................................... 10
CHAPTER 3: IDENTIFICATION OF A NOVEL MISSENSE MUTATIONFXNW168R ............................................................................................................. 32
CHAPTER 4: G130V ALLEVIATES MITOCHONDRIA DYSFUNCTION ............ 46
CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS ............................ 65
REFERENCES .................................................................................................... 74

viii

LIST OF TABLES
Table 2.1 Clinical measures comparing FRDA homozygous and heterozygous
patients............................................................................................................................45
Table 2.2 Clinical measures comparing FXNG130V and FXNI154F patients with other
FRDA heterozygous patients...........................................................................................46

ix

LIST OF FIGURES
Figure 2.1 Selected FRDA-associated missense mutations decrease FXN81–210
levels………………………………………..........................................................................39
Figure 2.2 Selected FRDA-associated missense mutations do not impair FXN
association with mitochondria…………………………………………………………………40
Figure 2.3 Selected FRDA-associated missense mutations impair processing from
FXN42–210 to FXN81–210……….……………………………..…………..………………………41
Figure 2.4 Missense mutations I154Fand G130V enhance the association of FXN42–210
with MPP..……………………………………..…………………………………………..……42
Figure 2.5 Increasing G130V and I154F FXN1–210 levels does not increase FXN81–210
levels..………………………………….…………………………………………..……………43
Figure 2.6 Impaired FXN processing from FXN42–210 to FXN81–210 occurs in fibroblasts
from FRDA patients with G130V……………………………………………………......……44
Figure 3.1 W168R decrease FXN81–210 levels…………………………………………….…56
Figure 3.2 W168R does not impair FXN association with mitochondria………...……….57
Figure 3.3 W168R enhances the association of FXN42–210 with MPP…………………….58
Figure 3.4 W168R impairs processing from FXN42–210 to FXN81–210 ...…………...……….59
Figure 3.5 Increasing W168R FXN1–210 levels does not increase FXN81–210 levels…...…60
Figure 4.1 Decreased mitochondrial ferritin in as absent in G130V patient
fibroblasts……………………………………………………………………………….…..…..73
Figure 4.2 Increased Mitochondria Aconitase Activity in G130V FRDA patient
fibroblasts……………………………………………………………………………….…..…..74
Figure 4.3 Increased TCA metabolic activity in G130V FRDA patient fibroblasts……....75
Figure 4.4 G130V Patients have retained mitochondria structure and increased
glycogen………………………………………..……………………………………….…..…..76
Figure 4.5 Mitochondria fragmentation in FRDA patient fibroblasts……..……………….77
Figure 4.6 Mitochondria fusion is preserved in G130V patient fibroblasts…………...….78
x

Supplemental Figure 4.2 FXN overexpression reverses mitochondria fragmentation…79

xi

ABBREVIATIONS
9HPT

9 Hole peg test

ADL

Activities of daily living

ATP

Adenosine triphosphate

BCA

Bicinchoninic acid

BSA

Bovine serum albumin

CNS

Central nervous system

CTRL

Control

CoQ10

Coenzyme Q10

DNA

Deoxyribonucleic acid

DRG

Dorsal root ganglia

DTT

Dithiothreitol

ECL

Enhanced chemiluminescence

EDTA

Ethylenediaminetetraacetic acid

FARS

Friedreich ataxia rating scale

Fe-S

Iron-Sulfur

xii

FRDA

Friedreich ataxia

FtMt

Mitochondrial Ferritin

FXN

Frataxin

GAA

Guanine-Adenine-Adenine

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GFP

Green Fluorescent Protein

HA

Hemagglutinin

HCL

Hydrogen chloride

HDAC

Histone deacetylase

HDACi

Histone deacetylase inhibitor

HEK293

Human embryonic kidney cells

HMZ

Homozygous

HRP

Horseradish peroxidase

HTZ

Heterozygous

ISC

Iron sulfur cluster

IgG

Immunoglobulin

IP

Immunoprecipitation

xiii

LC-MS

Liquid Chromatography Mass Spectrometry

MG132

Proteosome inhibitor

MITO

Mitochondria

MPP

Mitochondria processing peptidase

mRNA

Messenger ribonucleic acid

MRI

Magnetic resonance imaging

OXPHOS

Oxidative Phosphorylation

PAGFP

Photoactivatable green florescent protein

PVDF

Polyvinylidene difluoride

RNA

Ribonucleic acid

ROS

Reactive oxygen species

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

SEM

Standard error of the mean

SOD

Superoxide dismutase

T25FW

Timed 25-foot walk

TCA

Tricarboxylic acid

WT

Wild type

xiv

Z-score

Performance measure

xv

Chapter 1: Introduction to Friedreich ataxia
1.1 Friedreich ataxia Pathogenesis
Friedreich’s Ataxia (FRDA) is an autosomal recessive, neurodegenerative
disorder that affects 1 in every 50,000 people in the United States. FRDA was first
described in 1863 as a disease that is primarily early onset, associated with progressive
limb and gait ataxia, absent tendon reflexes in the legs, axonal sensory neuropathy,
dysarthria, muscle weakness, scoliosis, spasticity in the lower limbs, and loss of position
and vibration sense.9,47 Neurodegeneration occurs in the dorsal root ganglia (DRG), with
loss of large sensory neurons, as well as degeneration of posterior columns, and atrophy
of the corticospinal tracts and spinocerebellar tracts of the spinal cord and the dentate
nucleus in the cerebellum. There is also loss of pancreatic islet cells and hypertrophic
cardiomyopathy, which is the most common cause of death among FRDA patients.
FRDA is characterized by decreased expression of the frataxin (FXN) protein,
from the FXN gene on chromosome 9. This is caused by Guanine-Adenine-Adenine
(GAA) trinucleotide repeats within intron 1 of the FXN gene.22,41,44,114 In typical FRDA
patients the length of the allele with the shorter GAA expansion inversely correlates with
FXN levels, age of onset, and rate of disease progression; longer alleles result in earlier
onset and a faster progression.41,44,86 Expanded GAA repeats may form unusual triplex
structures, disrupting RNA polymerase and preventing transcription elongation.8
Epigenetic mechanisms of decreased FXN levels have been observed as regions
flanking GAA repeat expansion exhibit marks of condensed heterochromatin. There is
also increased methylation of specific CpG sites, reduction of histone H3 and H4
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acetylation levels and increased histone H3 lysine 9 (H3K9) trimethylation in FRDA
lymphoblasts, peripheral blood, brain and heart tissues.3,24,55,57
1.2 Frataxin Function
Typical FRDA patients carry less than 10% of control FXN levels, which correlate
with disease severity.41 FXN is a highly conserved mitochondria protein that is important
for proper mitochondria function, but the mechanism by which decreased expression
leads to disease pathology is unknown. The FXN gene is composed of seven exons
(exons 1–4, 5a, 5b and 6), with exons 4 and 5a being the most conserved. The crystal
structure of FXN, containing amino acid residues 81-210, forms a large, twisted, sixstranded β-antiparallel sheet, flanked by N- and C-terminal α helices (α1and α2). The
negatively charged residues on the helical plane are proposed to be involved in iron
binding,1 while the uncharged residues on the surface beta sheet are likely to be
responsible for protein–protein interactions.
Frataxin is translated by cytoplasmic ribosomes,106 and translocated to the
mitochondria by an N-terminal mitochondria localization sequence. Upon entry into the
mitochondria,68 FXN undergoes two-step proteolytic cleavage by mitochondria
processing peptidase (MPP) to generate the mature protein consisting of amino acids
81-210.13,25
Many studies have implicated FXN as a key player in iron metabolism, iron
storage and iron-sulfur cluster biogenesis.23,30,38,60,68,71,80,94,95,110,123, A conserved primary
Fe2+ binding site, with a dissociation constant within the micromolar range (3–55 µM),
involves residues of the acidic ridge localized within the first alpha helix.32,81,87,123 In
addition to Fe binding, FXN interacts with mitochondrial aconitase, ferrochelatase and
proteins of the mitochondrial Fe-S cluster machinery.6,15,50,124 Fe is essential for
2

metabolic processes including oxygen transport, electron transport, DNA synthesis,
redox/non-redox reactions and other cell functions.42,75 In the central nervous system
(CNS) and brain, where energy requirements are high, ATP is in high demand for
synaptic transmission and distant axoplasmic transport, all of which involve iron-sulfur
enzymes of oxidative metabolism.31 Fe-S containing proteins play a crucial role in
cellular respiration and ATP production, therefore decreased activity has significant
effects on mitochondria function.15,30 FXN’s role in iron sulfur cluster biogenesis makes it
essential for enzymatic activity of Fe-S containing aconitase and respiratory chain
complexes. Consequently, decreased FXN results in decreased aconitase activity, both
in cell culture models and in vivo,59,65,91,117,119 and in heart tissues and biopsies of FRDA
patients.65,70,85,97,102
1.3 FXN Deficit Leads to Mitochondria Dysfunction
Overexpression of FXN shows it to be an active participant in pathways of
mitochondrial energy conversion and oxidative phosphorylation (OXPHOS), as well as a
regulator of the Krebs Cycle.101 Dysregulation of cell and mitochondrial iron metabolism
is a common pathogenic mechanism among neurological diseases; therefore, an
emphasis on the role of mitochondria in FRDA pathogenesis has been increasingly
explored.99
Energy production through oxidative OXPHOS is the primary function of
mitochondria for maintaining optimum cellular activity. The electron transport chain,
consisting of a series of complexes, transfers electrons from donors to acceptors in
order to generate a proton gradient used to produce adenosine triphosphate (ATP) by
OXPHOS. It has been suggested that there is a direct interaction between FXN and
complex II subunits, suggesting a role for FXN in the electron transport chain.52,118
3

Therefore, FXN deficiency could lead to decreased energy production and mitochondrial
respiration. Decreased Complex I, II and III activity has been observed in
endomyocardial biopsies of FRDA patients,102 and FRDA mouse models demonstrate
impairment of mitochondrial biogenesis and OXPHOS dysfunction in respiratory chain
complexes I, II and IV.33,76
OXPHOS is the primary source of reactive oxygen species (ROS), O2- and H2O2.
Although produced throughout the cell, 90% comes from mitochondrial
respiration.4,46,58,120 These toxic products of respiration adjust the physiological redox
balance leading to oxidative stress. O2- in excess can inactivate Fe-S containing
enzymes leading to the release of iron and increased redox-active iron pool. The exact
mechanism by which decreased FXN leads to oxidative stress in unknown. It is
proposed that iron, which is mobilized by O2− and H2O2, can participate in the Fenton
reaction:
Fe(II) + H2O2 → Fe(III) + HO+ HOto produce a toxic hydroxyl radical (HO). The hypothesis that frataxin deficiency leads to
enhanced Fenton reaction as a contributor of FRDA pathogenesis is supported by
increased ROS and mitochondrial iron deposits in FRDA tissues.2,12,16,27,43,61,63,70,88,107,108,
111,112,118

Under physiological conditions, superoxide dismutases (SODs) are the first line

of defense against ROS, converting O2- into H2O2,17 as well as scavenging enzymes and
small antioxidant molecules; however, this response was found to be compromised in
FRDA patient fibroblasts.78,93
Furthermore, energy production and respiratory chain complexes are also
important for mitochondria network dynamics. Human fibroblasts carrying genetic
changes in the subunits of the respiratory chain complexes show a fragmented
4

mitochondrial network.66,67 Few data on the mitochondrial network structure in frataxindeficient cells are available, and the mitochondrial response to different stresses will
depend on the cell type physiology, cell adaptation capacity and biological
microenvironment.53
1.4 Clinical Trials and Therapeutic Strategies
At present there is no cure or effective treatment for FRDA. Frataxin function
remains to be elucidated; current strategies aim to increase FXN expression or target
downstream pathways affected secondary to FXN deficiency. High-throughput
screening with different cellular models is also being used to search for new drugs.18
1.4.1 Antioxidants and oxidative phosphorylation
FXN deficiency causes cells to be highly sensitive to damage caused by
oxidative stress, suggesting antioxidants could be a therapeutic approach for FRDA.
Idebenone is a short-chain CoQ10 analogue that acts as an antioxidant by protecting
membrane lipids from peroxidation and stimulating OXPHOS and ATP production by
carrying electrons from complexes I and II to complex III in the electron transport chain.84
Idebenone was first identified as a candidate for treatment of FRDA105 based on its
ability to protect the respiratory complex II from iron inactivation and decreased
lipoperoxidation. Studies have suggested it improves neurologic functions.39
Furthermore, treatment of three FRDA patients resulted in reduction of myocardial
hypertrophy.105 Idebenone, even at high doses, appears safe and well-tolerated,
however results were not replicated in more systematic trials and it appears to have no
effect on disease progression and the neurologic status in patients as compared to
placebo.
5

Treatment of patients with Idebenone or a combination of coenzyme Q10 (CoQ10)
with vitamin E to improve mitochondrial function and to reduce oxidative stress has been
explored. Vitamin E is a natural antioxidant that is lipid-soluble and highly abundant in
nuclear and mitochondrial membranes. CoQ10 is an electron carrier in the respiratory
chain and is involved in the reduction of oxidized vitamin E. When FRDA patients were
treated with this combination there was improvement in cardiac and skeletal muscle
bioenergetics, however there was no observed benefit on cardiomyopathy.56
Other CoQ10 analogues have been developed such as MitoQ, which specifically
targets mitochondria and has been shown to protect patient fibroblasts from endogenous
oxidative stress effectively.62 However, MitoQ does not exchange electrons in the
respiratory chain, and cannot be regenerated to stimulate OXPHOS, creating a limitation
to this treatment in clinical trials.
1.4.2 Iron chelating strategy
The pathogenesis of FRDA seems to involve an imbalance in the intracellular
accumulation of iron, with mitochondrial accumulation and relative cytosolic depletion.
One therapeutic approach for this is iron chelation, which is the current treatment of
systemic iron overload diseases. Limitations to iron chelators as a therapeutic include
membrane permeability and specific redistribution of iron from mitochondria without
compromising overall cellular availability.98 For example, Desferoxamine chelates iron in
the extracellular compartment and cytosol, promoting cellular iron depletion, but has
poor membrane penetration and cannot be given orally. Studies also found that it
reduces Fe(II) toxicity on mitochondrial complex II, but also decreases aconitase
activities and down-regulates frataxin.10,74,105 Consequently it cannot be used to treat
FRDA.
6

Alternatively, Deferiprone is an iron chelator that localizes to the mitochondria98,
rapidly distributes in the CNS, crossing membranes, and can penetrate mitochondria to
remove excess iron. Deferiprone has a low affinity for iron and less tendency to cause
overall iron depletion.115 It restores mitochondrial redox potential, reduces ROS,
prevents apoptosis and increases aconitase activity, without affecting frataxin levels;51,64
it is well tolerated and can be administered orally. However, worsening of tremor
occurred at higher doses and the risk of agranulocytosis remains a threat of deferiprone
treatment.
1.4.3 Histone deacetylase inhibitors
Histone deacetylases (HDACs) inhibitors (HDACi) have been proposed to
counteract the chromatin-condensing effect of the GAA repeat expansions and to restore
frataxin expression in FRDA. HDACi revert silent heterochromatin to an active chromatin
conformation with both positive and negative effects on gene expression.40,100 Such
molecules aim to restore the transcriptional deficit at the FXN gene in patients; however,
changes in gene transcription could further exacerbate the existing FRDA pathology.
1.5 Frataxin missense mutations
2-3% of FRDA patients carry a GAA expansion on one FXN allele, and a
missense mutation on the other. Many disease-associated missense mutations in the
C-terminus end of FXN have been identified, yet few have been characterized in vivo or
in situ. Some are proposed to disrupt mRNA expression (various splice site mutations
such as c.165 + 1 G>A and c.384 −2 A>G),34,109 translation initiation (c.1A>T, c.2T>C,
c.2delT, c.3 g>T, c.3G>A), or protein folding (L106S).7,25,38,48 These should produce little
to no functional protein, and their associated phenotype should be severe in conjunction
7

with a long GAA repeat on the other FXN allele. In contrast, R165C, W155R, G130V,
and I154F mutations are suspected to produce stable protein. However, R165C and
W155R lead to biochemical deficiencies in vitro.14,116 The mechanism behind the
disease-causing features of G130V and I154F is less clear, having been suggested to
reflect abnormal maturation or dysfunctional FXN in different models.48
The phenotype associated with these patients cannot be predicted with such
certainty; these patients can have a mild or severe clinical outcome45 creating a unique
platform to understand clinical heterogeneity. Lower processing efficiency or functional
alterations caused by the modification of amino acids are proposed contributors to
pathogenicity of missense mutations.25 Impaired protein maturation correlates with
impaired protein stability;25 however, presently there is no consensus regarding the
impact of the selected mutant variants upon protein maturation. Therefore, it is important
to investigate if these mutant FXN alleles can be properly processed to the mature form
in order to assess their presence in mitochondria and ascertain if it correlates with
phenotype.
Defining how missense mutations influence FXN’s processing and role in energy
production and cellular metabolism will help identify pathways that are affected during
disease progression and begin to explain the varying phenotypes and establish a
genotype-phenotype correlation.
1.6 G130V missense mutation
Of all disease-associated mutations, patients carrying the G130V missense
mutation are of most interest because they have less than 5 % of control mature FXN
levels but evolve to a milder phenotype than patients with 2 GAA repeats. In a large
8

cohort of FRDA subjects, those with the G130V mutation have significantly lower
occurrence of cardiomyopathy, scoliosis, and diabetes, and they surpass other point
mutation carrying subjects on composite performance measures. They demonstrate
greater neurological function and decreased disease severity at a similar disease
duration.7,19,34,36,37,45,49,82,83,90,125 Additionally, primary patient fibroblasts from G130V
patients grow at rates similar to controls and faster than typical FRDA patients. In
chapter 2 I identify the mechanism by which FXN missense mutations result in lower
mature FXN81-210 levels, and in chapter 3 I present a novel FXN missense mutation and
the possible mechanism underlying its association with severe FRDA phenotype. Finally
in chapter 4, I assess the multiple features of mitochondrial dysfunction associated with
severe phenotype in typical FRDA, and compare them to G130V patients in order to
understand the molecular mechanisms underlying the milder phenotype.
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Chapter 2: Selected Missense Mutations Impair FXN Processing
2.1 Abstract
In typical FRDA, the shortest GAA expanded allele correlates with FXN levels
and disease severity, including age of onset and progression rate. The phenotype of
patients who carry a GAA expansion on one allele and a missense mutation on the other
allele cannot be predicted with certainty; these patients can have a mild or severe
clinical outcome,8 Many missense mutations in the C-terminus of FXN have been
identified in FRDA; however, few have been characterized, and the mechanism by which
missense mutations lead to disease pathology is not entirely known. With the absence of
GAA repeats on the second allele, the mechanism by which FXN missense mutation
result in lower mature FXN81-210 levels must first be understood. I154F, W155R and
R165C have been characterized as dysfunctional mutations,14,116 by in vitro assays.
G130V, W168R, and G137V are located predominantly on the surface of FXN and their
effects on FXN function have not been described.
In this chapter, the effects of FRDA-associated missense mutations on FXN
import into the mitochondria by immunocytochemistry and subcellular fractionation, FXN
processing from precursor to mature form by western blot, and FXN interaction with
MPP by co-immunoprecipitation were investigated. These studies have identified that
the effects of disease-associated mutations on FXN processing lead to abnormal FRDA
phenotype in mutation selective ways.
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2.2 Introduction
FXN is important for proper mitochondrial function, but the mechanism by which
decreased expression leads to disease pathology is not entirely known.52 FRDA is most
commonly caused by an expansion of a GAA trinucleotide repeat in the first intron of
the FXN gene on both alleles. 2-3% of FRDA patients carry GAA repeats on one allele
accompanied by a point mutation on the other FXN allele. In typical FRDA, the length of
the shortest GAA expansion correlates with disease severity; longer GAA expansions
result in earlier onset and a faster progression.41,44,86 The phenotype of patients who
carry a GAA expansion on one allele and a missense mutation on the other allele cannot
be predicted with certainty; these patients can have a mild or severe clinical outcome,45
creating a unique platform to understand clinical and genetic heterogeneity.
Upon entry into the mitochondria, precursor FXN1–210 is processed by
mitochondria processing peptidase (MPP) into intermediate FXN42–210, followed by
mature FXN81–210. Many missense mutations in the C-terminus of FXN have been
identified in FRDA, yet few have been characterized in vivo or in situ. Some are
proposed to disrupt mRNA expression (various splice site mutations such as
c.165 + 1 G>A and c.384 −2 A>G),34,109 translation initiation (c.1A>T, c.2T>C, c.2delT,
c.3 g>T, c.3G>A), or protein folding (L106S).7,25,38,48 These should produce little to no
functional protein, and their associated phenotype should be severe in conjunction with a
long GAA repeat on the other FXN allele. In contrast, R165C, W155R, G130V, and
I154F mutations are suspected to produce stable protein. However, R165C and W155R
lead to biochemical deficiencies in vitro.14,116 The mechanism behind the
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disease-causing features of G130V and I154F is less clear, having been suggested to
reflect abnormal maturation or dysfunctional FXN in different models.48
Patients that carry missense mutations, despite milder disease severity in many
cases, generally have lower FXN protein levels compared to patients with GAA repeat
expansions on both alleles72, suggesting that the clinical outcome cannot be explained
by decreased FXN expression alone. DNA transcription is not affected by point
mutations as evidenced by mRNA levels in people carrying a G130V mutation that are
comparable to controls.7 Our hypothesis is that the disease-causing effect of missense
point mutations are posttranslational, thus possibly affecting protein processing.
In this chapter I assess the effects of FRDA-associated missense mutations:
R165C, W155R, I154F, G130V, G137V, and L106S on FXN import into the
mitochondria, processing from precursor to mature form, and interaction with MPP.
Selected disease-related FXN missense mutations impair FXN localization, and selected
mutations lead to higher levels of partially processed FXN as well as enhanced
interactions with mitochondria processing peptidase. I also assess if impaired processing
could be overcome by increasing FXN precursor levels. Finally, I examined a large
natural history study to investigate whether patients carrying missense point mutations
displayed distinct clinical abnormalities that could be related to the altered processing
observed in vitro. I believe the incompletely processed FXN42–210 in patients carrying a
G130V or I154F mutation carries some residual activity, possibly contributing to the
milder phenotype.
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2.3 Materials and Methods
2.3.1 Site-directed mutagenesis

Each FXN mutant was created using the pcDNA3.1 plasmid with wild-type
human FXN containing a C-terminus hemagglutinin (HA) tag (Addgene Plasmid #31895)
and the Agilent QuikChange XL Site-Directed Mutagenesis Kit.

2.3.2 Transfection and immunostaining
Human embryonic kidney (HEK 293) cells were grown on coverslips and
transfected via Lipofectamine 2000 reagent with 4 µg of DNA (2 µg FXN and 2 µg
mito-GFP). Twenty-four hours after transfection, cells were fixed with 4%
paraformaldehyde followed by treatment with blocking buffer containing 5% normal goat
serum, 3% Triton X-100, and 1% BSA. Primary antibody to the HA epitope was added at
a 1:100 dilution overnight. Alexa Fluor 568 secondary antibody was added at a dilution
of 1:100 and cells were imaged by confocal microscopy.
2.3.3 Subcellular fractionation and western blot
Following transfection of FXN-mutant constructs, HEK 293 cells were lysed with
buffer containing: 150 mmol/L sodium chloride, 1 mmol/L EDTA, 100 mmol/L Tris-HCl,
1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and protease
inhibitor cocktail (Millipore #539134) 1:1000 at pH 7.4 for 1 h and centrifuged at 150g to
collect whole cell lysates. Whole cell lysates were centrifuged at 100g followed by
150g to separate the soluble mitochondria fraction from the cytosolic fraction, and
100g to collect insoluble mitochondria pellet from soluble mitochondria fraction using a
13

Thermo Scientific Mitochondria Isolation Kit for Mammalian Cells (#89874). The protein
concentration of each fraction was determined using a BCA protein assay, and 4 µg of
each fraction was loaded on a 12% NuPage gel for electrophoresis, followed by transfer
to nitrocellulose membranes. Membranes were blocked with 3% milk for 1 h and
incubated with primary HA antibody overnight at 4°C. Membranes were then incubated
with secondary HRP-conjugated antibody for 2 h and immunoreactive bands were
visualized using luminol-enhanced chemiluminescence (ECL) HPR substrate.
2.3.4 Coimmunoprecipitation and western blot
Twenty-four hours after transfection, cells were lysed with buffer containing: 150 mmol/L
sodium chloride, 1 mmol/L EDTA, 100 mmol/L Tris-HCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, and protease inhibitor cocktail (Millipore
#539134) 1:1000 at pH 7.4 for 1 h. For coimmunoprecipitation, 2 µg of MPP primary
antibody was added to 800 µg of total lysate and rocked for 2 h at 4°C. The lysate and
antibody solution was then added to washed Protein G Agarose beads overnight,
rocking back and forth at 4°C. The following day the beads, lysate, and antibody solution
were centrifuged at 14,000g and washed five times with IP lysis buffer containing:
150 mmol/L sodium chloride, 1 mmol/L EDTA, 100 mmol/L Tris-HCl, 1% Triton X-100,
and 0.5% sodium deoxycholate at pH 7.4. Sample buffer (2X) was added to the beads
and heated to 100°C for 5 min. The immunoprecipitated proteins were loaded on a 12%
NuPage gel. Normal IgG primary antibody was used as a control as well as anti-FXN
primary antibody, followed by Trueblot secondary HRP-conjugated antibody (Rockland
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#18-8841-31) to detect immunoreactive bands.
2.3.5 MG132 Treatment
Transfected cells were treated with 10 µmol/L of MG132, cell-permeable
proteasome inhibitor, for 5 h. Following cell lysis, equal amounts of total cell lysate were
loaded on a 12% NuPage gel.

2.3.6 Fibroblast FXN levels by Western Blot
Primary fibroblasts from healthy controls and FRDA patients with point mutations
were lysed in buffer (0.25 mol/L NaCl, 5 mmol/L EDTA, 50 mmol/L HEPES [pH 7.5],
0.1% NP-40, 0.5 mmol/L DTT) supplemented with 0.1% protease inhibitor cocktail
(Sigma Aldrich) and kept on ice for 20 min. The lysates were centrifuged at 20,000g for
10 min at 4°C. The clarified supernatants were transferred to fresh tubes and protein
concentrations were determined by Bradford assay. A quantity of 75 µg of whole cell
lysate were separated by SDS-PAGE and transferred to a PVDF membrane.
Immunoblotting was performed with antibodies against FXN (Santa Cruz Biotechnology)
and GAPDH (Millipore), and the signals were detected by HRP-mediated
chemiluminescence. Densitometry was performed using Image J software (NIH), and the
calculated signal ratio of FXN42–210 to FXN81–210 in each group is plotted. The bars
represent the average signal for each group: CTRL= 5 fibroblast lines (n = 13), G130V
=3 lines (n = 17), and Typical = 7 lines (n = 8). The asterisk indicates significant
differences as determined by Student's t-test (P < 0.05).
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2.3.7 Quantification and statistical analysis
Image J Software was used to quantify FXN levels on western blots and is
represented as mean ± SEM. Two-tailed Student's t-test was used to compare mutants
to WT. Significance was set at P < 0.05. Image J software was also used to calculate
Pearson's correlation coefficient for quantification of colocalization in
immunofluorescence images.

2.3.8 Clinical measures
Clinical measure results were derived from a long-standing natural history study
from 12 American and Australian sites.92 In this study, data is collected annually on
clinical features of > 900 individuals with FRDA. Data from the baseline cross sectional
visits were used in this study including overall medical history and scores on the
Friedreich Ataxia Rating Scale (FARS) (a quantified neurological exam); Ataxia Staging
scale (a disability score); the Timed 25-Foot Walk (T25FW), scored as the reciprocal (a
simple performance test of walking); 9-Hole Peg Test (9HPT), scored as the reciprocal
(a simple test of hand function); Contrast Letter Acuity test, the sum of the number of
letters read on each of three Sloan charts (a quantitative test of vision); and an Activities
of Daily Living (ADL) scale. All these measures capture progressive neurological
dysfunction in FRDA. The performance measures were also transformed into Z-scores
to create composite scores as reported previously. The Z2 composite is the sum of the
Z-scores from T25FW and 9HPT. The Z3 composite is the sum of Z-scores from T25FW,
9HPT, and overall vision tests.
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2.4 Results
2.4.1 Selected FRDA-associated missense mutations decrease FXN81–210 levels, but do
not impair FXN association with mitochondria
To determine the effects of FRDA-associated missense mutations on FXN import
into the mitochondria, FXN variants containing a C-terminal HA tag were cotransfected
with mito-GFP in HEK 293 cells. Levels of the FXN81–210 form of I154F and G130V are
lower as determined by western blot compared to WT, while no detectable exogenous
FXN81–210 was detected following transfection of G137V and L106S constructs (Fig. 2.1).
Confocal microscopy imaging was used to determine localization of the exogenous FXN
proteins. R165C and W155R co-localize with mito-GFP and have FXN immunoreactivity
comparable to WT (Fig. 2.2A). I154F, G130V, and G137V colocalize with mito-GFP but
have lower FXN immunoreactivity compared to FXNWT (Fig. 22.2B). Finally, transfection
of L106S leads to no FXN immunoreactivity (Fig. 2.2C). All expressed mutant proteins
colocalize with mito-GFP with a Pearson's correlation coefficient greater than 0.98. While
R165C and W155R have increased immunoreactivity compared to I154F, G130V, and
G137V, the I154F, G130V, and G137V proteins retain their mitochondrial localization.

2.4.2 Selected FRDA-associated missense mutations impair processing from FXN42210

to FXN81–210
To investigate further the decrease in FXN81–210 levels of particular FXN-mutant

proteins, subcellular fractionation and separation of the soluble mitochondrial fraction
and the insoluble mitochondrial pellet was performed. Consistent with
immunocytochemistry results, transfection of R165C or W155R leads to FXN81–210 levels
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comparable to levels of FXNWT, while transfection of I54F or G130V produces lower
levels of FXN81–210 (Fig. 2.3A and 2.3B). While I154F or G130V lead to low FXN81–
210

levels, expression of these mutant proteins leads to an increased level of FXN42–

210

(Fig. 2.3A and C), suggesting these FXN variants are not processed readily from

FXN42–210 to the FXN81–210 form. Furthermore, these variants also have increased ratios
of insoluble to soluble FXN42–210 (Fig. 2.3E-G), suggesting these proteins remain
associated with the insoluble inner mitochondrial membrane rather than being released
into the soluble portion of the mitochondrion.

2.4.3 Missense mutations FXNI154F and FXNG130V enhance the association of FXN42–
210

with MPP
To examine the mechanism by which I154F and G130V impair FXN processing,

FXN-mutant proteins were co-immunoprecipitated to study the strength of the interaction
between FXN and MPP. The FXN42–210 forms of I154F and G130V are more readily coimmunoprecipitated by anti-MPP than the FXN42–210 form of WT, R165C, and W155R
proteins (Fig. 2.4), suggesting stronger attachment between these variants and MPP.

2.4.4 Increasing FXNG130V and FXNI154F FXN1–210 levels does not increase FXN81–
210

levels
Traditional therapies for FRDA include several strategies designed to increase

FXN levels. To model this approach, transfected cells were treated with 10 µmol/L
MG132, a proteasome inhibitor, to increase FXN1–210 levels in an effort to overcome
impaired FXN processing. While G130V and I154F FXN1–210 levels increased, as did
FXN42–210 levels, MG132 treatment did not increase FXN81–210 levels (Fig. 2.5).
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This suggests that amelioration of these missense mutations cannot be achieved with
simple overexpression of precursor FXN, and that there is a true impediment to
processing of these mutants to the FXN81–210 form.

2.4.5 Impaired FXN processing from FXN42–210 to FXN81–210occurs in fibroblasts from
FRDA patients with FXNG130V
To analyze the significance of these findings in patient-derived cells and examine
the processing of native FXN, western blots were performed on whole cell extracts
prepared from control (CTRL) and FRDA G130V primary patient fibroblasts.
Endogenous FXN42–210 and FXN81–210 FXN levels were detected and expressed as a ratio
of FXN42–210/FXN81–210 (Fig. 2.6A). The ratio of FXN42–210 to FXN81–210 is increased in
FRDA G130V patient fibroblasts compared to controls (P < 0.05). Patient fibroblasts
were also immunostained with antibodies to FXN and mitofusin. FRDA G130V patient
fibroblasts contain large globular structures (Fig. 2.6B) consistent with the increased
insoluble FXN42–210 form detected by western blot and overexpression studies.

2.4.6 FRDA patients with FXNG130V have milder disease features and slower disease
progression compared to other heterozygous FRDA patients
We then sought to establish whether patients carrying missense point mutations
displayed distinct clinical abnormalities that could be related to the altered processing
observed in vitro. Heterozygous (HTZ subjects) FRDA patients, with a missense
mutation on one FXN allele and GAA expansion on the other, and typical homozygous
(HMZ subjects) FRDA patients, with GAA expansions on both FXN alleles, have different
clinical profiles when examined in a large natural history study (Table 2.1). In addition,
patients carrying G130V mutations have significantly lower occurrence of
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cardiomyopathy, scoliosis, and diabetes, the most severe components of the disease,
compared to other HTZ subjects (Table 2.2). Furthermore, clinical measures at baseline
exam including ataxia stage, activities of daily living (ADL) scores, 9HPT-1, T25FW-1,
Vision, 9HPT, Z2, and Z3 were significantly worse in other HTZ subjects, even though
the groups were of similar disease duration, suggesting a less severe phenotype in
G130V patients (Table 2.2). Patients with an I154F mutation fell between the phenotypic
severity of G130V and other point mutations analyzed.
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2.5 Discussion
In this chapter, FRDA-causing mutations G130V and I154F decrease FXN81–
210

levels, but do not impair FXN localization to mitochondria. G130V and I154F appear

to impair FXN processing from FXN42–210 to FXN81–210, as well as enhance binding of
FXN42–210 to MPP. This impaired processing is also observed in primary fibroblasts from
FRDA patients with a G130V mutation. Increasing G130V and I154F precursor levels
does not lead to an increase in FXN81–210 levels, but does increase levels of FXN42–210.
These are all consistent with a defect in peptide processing of these forms being a
pathogenic mechanism in patients carrying these mutations. In addition, these two
forms, especially G130V, are associated with milder features of FRDA than other point
mutations or expanded GAA repeats, suggesting that these mild phenotypes may reflect
the underlying FXN biochemistry.
In heterologous systems, disease-associated mutations in FXN are abnormal in
several mutation selective ways. The inability to detect L106S and G137V by
immunostaining and western blot supports modeling studies suggesting that mutations
residing within the protein core decrease protein stability.48 In vitro functional studies
have also characterized R165C and W155R as dysfunctional mutations, causing
decreased binding of FXN to Fe-S cluster assembly complex.14,116 Moreover, R165C and
W155R had levels of FXN81–210 that were comparable to WT, and there was no evidence
for impaired processing of these two mutant forms from FXN42–210 to FXN81–210. Further
functional studies in vivo may provide a correlation between the extent of dysfunction in
these two FXN-mutant proteins and severity of disease outcome.
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Abnormalities in FXN processing have been explored mostly in yeast and
bacteria expression systems.25,26,54,69 Here, we show an increased level of the FXN42–
210

form in disease-associated missense mutations associated with milder phenotypes,

not only in overexpression studies using mammalian systems, but also in primary
fibroblasts from FRDA patients. FRDA patients who carry G130V express lower FXN81–
210

levels than typical FRDA patients in fibroblasts, cheek swabs, and blood,72 yet have a

milder clinical phenotype (Tables 2.1 and 2.2). In a large cohort of FRDA subjects, even
though those with the G130V mutation have similar disease duration, they have
significantly better FARS and ADL scores than individuals with other point mutations.
FRDA G130V patients also have significantly lower occurrence of cardiomyopathy,
scoliosis, and diabetes, and they surpass other point mutation carrying subjects on
composite performance measures. As suggested in single cases previously, this
demonstrates that FRDA patients with G130V demonstrate greater neurological function
and decreased disease severity at a similar length of disease duration.
7,19,34,36,37,45,49,82,83,90,125

Patients with I154F mutations have clinical severities intermediate

between other patients with point mutations and G130V patients, matching the data from
cellular models of the molecular consequences of these mutants.
One explanation for the milder phenotype in patients carrying a G130V or I154F
mutation is that the incompletely processed FXN42–210 carries some residual activity. In
these mutants, this form is located in the mitochondria, and others suggest that FXN42–
210

can perform Fe-S cluster synthesis as well as participate in cysteine desulfurase

activity as efficiently as FXN81–210.73,117 Thus, the higher levels of FXN42–210 associated
with G130V could lead to the mild phenotype of patients with G130V if this intermediate
form is functional. Alternatively, it is possible that a small but clinically significant amount
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of the FXN42–210 form is slowly converted to the mature form, leading to the milder
phenotype in patients carrying G130V mutations compared with other mutations that
yield absolutely no mature FXN. Further experiments examining the functional abilities of
the FXN42–210 form of endogenous G130V may help clarify these possibilities. Overall,
the present study, in agreement with modeling studies and those in lower animal
expression systems, identifies multiple mechanisms in mammalian heterologous
systems by which FXN point mutations can lead to FRDA.
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Figure 2.1 FXN levels of disease-associated missense mutations. A. Western blot of
whole cell lysates collected from HEK 293 cells transfected with FXNWT, FXNR165C,
FXNW155R, FXNI154F, FXNG130V, FXNG137V, and FXNL106S. An anti-FXN antibody
was used to detect both exogenous FXN81–210 (15 kD) and endogenous FXN81–210
(14 kD) levels after transfection. B. Quantification of exogenous FXN levels was
normalized to FXNWT and endogenous FXN. Endogenous FXN serves as a loading
control. (***) = P < 0.0005.
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Figure 2.2 Selected FRDA-associated missense mutations do not impair FXN
association with mitochondria. Confocal microscopy images of HEK 293 cells
cotransfected with mutant FXN constructs and mito-GFP, fixed, and stained using a
primary anti-HA antibody to detect exogenous FXN only and secondary antibody Alexa
Fluor 568 (FXN). DAPI was also used as a nuclear stain. A. FXNWT, FXNR165C, and
FXNW155R. B. FXN154F, FXNG130V, and FXNG137V. C. FXNL106S. Pearson’s
correlation scatter plots of red and green signal intensities for each mutant were
generated using Image J Software.
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Figure 2.3 Selected FRDA-associated missense mutations impair processing from
FXN42–210 to FXN81–210. Following transfection of mutant constructs in HEK 293
cells, whole cell lysates were centrifuged to perform subcellular fractionation of soluble
mitochondria fraction and insoluble mitochondrial pellet. A. FXN levels were detected by
western blot using an anti-FXN antibody. Anti-SDHA antibody was used to detect SDHA
as a mitochondria marker and loading control. The soluble mitochondria fraction
includes: exogenous FXN42–210 (19 kD), exogenous FXN81–210 (15 kD), endogenous
FXN81–210 (14 kD), and SDHA (70 kD). The insoluble mitochondria pellet includes:
exogenous FXN42–210 (19 kD) and SDHA (70 kD). B. Percent FXN81–210 of total
FXN. C. Percent FXN42–210 of total FXN. D. Total FXN. E. Percent soluble FXN42–
210. F. Percent insoluble FXN42–210. G. Total FXN42–210. (*) = P < 0.05 and (***) = P
< 0.005
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Figure 2.4. Missense mutations FXNI154F and FXNG130V enhance the association of
FXN42–210 with MPP. Whole cell lysates from transfected HEK 293 cells were
immunoprecipitated with anti-MPP antibody and immunoblotted with primary anti-FXN
antibody. The same whole cell lysates were used as inputs for quantification analysis.
Western blot was used to detect FXN pulled down by anti- MPP. The Co-IP 19 kD blot
represents immunoprecipitated FXN42-210. The lysate 19 kD blot represents total
FXN42-210 in whole cell lysate. The graph represents fold change of FXN mutant
interaction with MPP compared to FXNWT.
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Figure 2.5 Increasing FXNG130V and FXNI154F FXN1–210 levels does not increase
FXN81–210 levels. Following transfection of HEK 293 cells with mutant FXN constructs,
cells were treated with 10 lmol/L MG132 proteasome inhibitor for 5 h followed by cell
lysis. Exogenous FXN1–210 (23 kD), FXN42–210 (19 kD), and FXN81–210 (15 kD)
levels, before and after treatment, were detected by western blot using a primary anti-HA
antibody.
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Figure 2.6. Impaired FXN processing from FXN42–210 to FXN81–210 occurs in
fibroblasts from FRDA patients with FXNG130V. FXN levels were quantified by western
blot using whole cell extracts from control (CTRL), FRDA, and G130V patient fibroblasts.
CTRL= 5 fibroblast lines (n = 13), G130V =3 lines (n = 17), and Typical = 7 lines (n = 8).
A. FXN42–210 (18 kD), and FXN81–210 (13 kD) levels from control (CTRL), G130V,
and typical FRDA were detected from whole cell extracts by western blot using an antiFXN antibody. Detection of GAPDH serves as a loading control. FXN levels are
quantified and expressed as a ratio of FXN42–210 to FXN81–210. (*) = P < 0.05. B.
Confocal microscopy images of patient fibroblasts (CTRL, FRDA, and G130V) that were
fixed and stained using primary anti-FXN (red) and primary anti-mitofusin antibodies
(green). Secondary antibodies included Alexa Fluor 568 (FXN) and Alexa Fluor 488
(mitofusin). DAPI was also used as a nuclear stain.
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HMZ

HTZ

N

741 (96%)

32 (4%)

Age of Onset

13.8

10.7*

BL age

26.5

24

Recent age

30

27.3

Duration

16.2

16.6

Sex (%female)

49.40%

43.80%

Non-ambulatory

50.20%

46.90%

Cardiomyopathy

57.80%

34.6%*

Scoliosis

82.40%

73.10%

Diabetes

5.50%

26.9%*

FARS

69.4

61.7

Stage

4

3.9

ADL

16.3

13.4

9HPT-1 (high = less severe)

0.014

0.025*

T25FW-1 (high = less
severe)

0.055

0.062

Vision

105.3

100.6

Z2 (high = less severe)

-0.09

0.48*

Z3 (high = less severe)

-0.08

0.26

*p<0.05
Table 2.1 Clinical measures comparing FRDA homozygous and heterozygous patients.
Patients who were heterozygous (HTZ) for the GAA repeat (those carrying point
mutations or deletions) had similar disease durations to those who were homozygous
(HMZ), but, aside from age of onset and presence of diabetes, were less severely
affected than homozygous patients. This was particularly true for measures containing
upper extremity function such as the nine-hole peg test and the Z2 score.*P < 0.05
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G130V

I154F

Other HTZ

N

9

3

18

Age of Onset (years)

10.8

11

11.5

BL age (years)

21.4

22.6

11.5

Recent age (years)

23.4

25

23.5

Duration (years)

12.4

14

15.9

Sex (%female)

44

67

44

Cardiomyopathy (%)

12.5

0

50

Scoliosis (%)

50

100

78.6

Diabetes (%)

12.5

6.7

35.7

FARS

40.6

54.3

72.4

Stage

2.4

3.5

4.5

ADL

5.8

8

17.5

9HPT-1 (high = less
severe)

0.044

0.029

0.015

T25FW-1 (high =
less severe)

0.139

0.117

0.026

Vision

127.8

125.5

85.3

Z2 (high= less
severe)

2.03

0.99

-0.21

Z3 (high = less
severe)

1.55

0.79

-0.38

Table 2.2 FRDA patients with FXNG130V have milder disease features and slower
disease progression compared to other heterozygous FRDA patients. Clinical data were
collected from a large natural history study of FRDA, including data on medical history,
genetic status, disability and activity of daily living (ADL) status, a quantitative
neurological exam (designated the Friedreich ataxia rating scale [FARS]), performance
measures, and two performance measure composites. When we fractionated the
heterozygous patients into patients those carrying G130V versus I154F versus others,
the G130V patients were markedly less affected. I154F patients had levels of
dysfunction between G130V and other heterozygous patients.
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Chapter 3: Identification of a Novel Missense Mutation- FXNW168R
3.1 Abstract
Friedreich’s Ataxia, a slowly progressive ataxia characterized by decreased
expression of the frataxin (FXN) protein, is caused by GAA trinucleotide repeats within
intron 1 of the FXN gene in 98% of patients. Two percent of patients with FRDA carry
one expanded GAA repeat in conjunction with a point mutation. In general, patients with
point mutations carry even lower FXN levels than typical FRDA patients. The
mechanism by which disease-associated missense mutations lead to disease pathology
is unclear, but occurs in mutation-selective ways by affecting protein folding, processing,
or function.
In this chapter the novel disease-causing W168R missense mutation is
introduced and its effects on FXN import into the mitochondria by immunocytochemistry
and subcellular fractionation, FXN processing from precursor to mature form by western
blot, and FXN interaction with MPP co-immunoprecipitation were investigated. These
studies have identified that W168R impairs FXN processing as a contributor to severely
low FXN levels, and a severe phenotype.
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3.2 Introduction
Typical FRDA is characterized by decreased expression of the frataxin (FXN)
protein, from the FXN gene on chromosome 9, caused by the presence of expanded
GAA trinucleotide repeats within intron 1 on both alleles. FXN is crucial for proper
mitochondrial function and iron-sulfur cluster biogenesis, but the mechanism by which
decreased protein expression leads to disease pathology is not fully known. 2% of
patients carry expanded GAA repeats on one allele, and a point mutation on the other
allele. These patients generally have lower FXN levels compared to typical FRDA
patients29,72. As intronic and frame shift point mutations lead to absence of functional
frataxin7,25,34,38,48,109, the phenotype in such patients is usually severe. In contrast patients
with missense mutations can have a mild or severe clinical outcome depending on the
exact mutation and the length of the GAA repeat on the opposite allele34,45,48,83,109. In
vitro studies allow one to distinguish between those affecting frataxin processing and
those altering overall levels (due to folding, RNA splicing or other severely pathogenic
processes). In vitro studies show that the specific location of missense mutations within
the protein structure has effects on protein folding (L106S)7,25,38,48 and decreased
participation in Fe-S cluster biogenesis (R165C, W155R)14,116.
A patient who carries a novel W168R missense mutation and 1133 expanded
GAA repeats on the opposite allele is presented in this chapter. The patient has
extremely low levels of mature FXN81-210 and an especially severe phenotype. The nonconservative W168R mutation is an amino acid switch from an aromatic, non-polar
tryptophan to a basic, electrically charged arginine at amino acid position 168 on Betasheet 5 of the human FXN crystal structure. Based on the amino acid position 168, it is
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anticipated that W168R destabilizes FXN and alters levels by misfolding. Our hypothesis
is that the W168R mutation impairs FXN processing, thus leading to very low FXN
levels. The effects of W168R on FXN import into the mitochondria, subcellular
localization, and interactions with mitochondria processing peptidase (MPP) were first
assessed. W168R is expressed predominantly as the intermediate FXN42-210 form, with
little to no expression of the mature FXN81-210 form consistent with patient samples, and
its localization to the mitochondria is not impaired. Increasing mature FXN levels with
W168R by modeling traditional therapies was also assessed, and indeed it did not. We
believe patients with W168R will require alternative approaches to repair FXN
processing from intermediate to mature form in order to increase FXN levels.
Furthermore, in addition to impairing FXN processing, we expect the W168R mutation
has another feature that alters FXN function, leading to a more severe phenotype.
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3.3 Materials and Methods
3.3.1 Transfection and Immunostaining
W168R was created using Addgene XL Site-Directed Mutagenesis Kit and
primers to pcDNA3.1-hFrataxin-HA (Plasmid #31895). Human Embryonic Kidney (HEK)
cells were co-transfected with 4ug of FXN and mitoGFP cDNA via Lipofectamine 2000
reagent. 24 hours after transfection, cells were fixed with 4% Paraformaldehyde followed
by treatment with blocking buffer containing 5% normal goat serum, 3% Triton X-100,
and 1% BSA. Primary antibody to the HA epitope was added at a 1:1000 dilution
overnight. Alexa Floura 568 secondary antibody was added at a dilution of 1:1000 and
cells were imaged by confocal microscopy.
3.3.2 Transfection, Subcellular Fractionation, and Western Blot
Following transfection of FXN mutants, HEK cells were centrifuged at 150 x g to
collect whole cell lysates. The soluble mitochondria fraction and insoluble mitochondria
pellet were collected using Thermo Scientific Mitochondria Isolation Kit for Mammalian
Cells (#89874). Protein concentration of each fraction was determined using BCA
Protein Assay and each fraction was loaded on a 12% NuPage Gel for electrophoresis,
followed by transfer to nitrocellulose membranes. Membranes were blocked with 3%
Milk for 1 hour and incubated with primary HA-antibody overnight at 4 °C. Membranes
were then incubated with secondary HRP-conjugated antibody for 1 hour and
immunoreactive bands were visualized using luminol-enhanced chemiluminescence
(ECL) HRP substrate.
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3.3.3 MG132 Treatment
HEK cells were transfected with FXNWT and W168R mutants via Lipofectamine
2000 reagent. 24 hours after transfection cells were treated with 10mM MG132 for 5
hours followed by cell lysis. Equal amounts of total lysate were loaded on a 12%
NuPage gel.
3.3.4 Quantification and Statistical Analysis
Image J Software was used to quantify FXN levels on western blots and is
represented as mean ± S.E.M. Two-tailed student’s t-test was used to compare W168R
to WT. Significance was set at P<0.05. Image J software was also used to calculate
Pearson’s

correlation

coefficient

for

immunofluorescence images.
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3.4 Results
3.4.1 Case History
A six-year old boy evaluated for ataxia, was historically smaller in size and slower
to progress developmentally than his fraternal twin brother. His height and weight were
consistently below the 1% percentile since birth. Hypotonia, decreased stamina,
clumsiness, and balance difficulties were noted around age two. When symptoms failed
to improve by age three, orthotics was prescribed, and physical therapy was initiated. At
age four, he was diagnosed with mild concentric left ventricular hypertrophy, diastolic
dysfunction as well as a scoliosis of 14 degrees. Initial testing included standard blood
work, a brain MRI, and ophthalmologic evaluation. Genetic testing performed to rule out
mitochondrial diseases ultimately rendered a diagnosis of Friedreich ataxia with GAA
repeats of 19 and 1133 and a novel W168R missense mutation. The subject’s father
carried this mutation and his mother carried an expanded GAA repeat.
3.4.2 W168R impairs FXN processing from intermediate to mature form, but does not
impair FXN association with mitochondria.
Based on western blotting of equal protein lysates, W168R is expressed
predominantly as the FXN42-210 form with nearly no detectable FXN81-210 immunoreactivity
compared to WT (Figure 3.1). To determine the effects of the W168R missense mutation
on FXN import into the mitochondria, the W168R variant containing a C-terminal HA tag
was co-transfected with mitoGFP in Human Embryonic Kidney (HEK 293) cells.
Confocal microscopy images with an antibody to the HA epitope, to detect exogenous
FXN only, show W168R co-localization with mitoGFP, but with lower levels of FXN
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immunoreactivity compared to WT (Figure 3.2). This data suggests that although W168R
decreases mature FXN levels, the immunoreactivity that remains is still associated with
mitochondria. To further examine the effects of W168R on FXN processing, coimmunoprecipitation of W168R and MPP shows enhanced interactions with the FXN42-210
form compared to WT (Figure 3.3). This is further demonstrated through subcellular
fractionation in which the FXN42-210 form of W168R is present in both soluble and
insoluble mitochondria fractions (Figure 3.4). This suggests that W168R impairs FXN
processing from the FXN42-210 to FXN81-210 form , and is retained with MPP at the inner
mitochondria membrane.
3.4.3 Increasing FXNW168R precursor levels does not lead to an increase in mature FXN
levels.
Traditional therapies for FRDA involve increasing FXN levels. To model this,
transfected cells were treated with 10mM MG132 protease inhibitor to increase
precursor FXN levels in an effort to overcome the impaired FXN processing by W168R.
W168R precursor levels increased, as did FXN42-210 levels, but not FXN81-210 levels
(Figure 3.5). This suggests that increasing mature FXN levels for W168R will require
alternative approaches to repair FXN processing from intermediate to mature form.
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3.5 Discussion
In this chapter a novel W168R FXN mutation is presented in a patients with a
single long GAA repeat on the other allele, and very low mature FXN81-210 levels with
early onset and significant disease progression. W168R is expressed predominantly as
the intermediate FXN42-210 form, with little to no expression of the mature FXN81-210 form,
but its localization to the mitochondria is not impaired. The G130V mutation, associated
with milder phenotype, is also expressed predominantly as the intermediate FXN42-210
form, with very low mature FXN81-210 form. However, the G130V mutation may provide
intermediate FXN functional capacity to compensate for lower mature levels.
Alternatively, low levels of G130V mature FXN levels may be sufficient to ameliorate the
phenotype, while W168R, one alpha helix turn away from the dysfunctional R165C
mutation, is in a unique position to impair both processing and potentially FXN
functionality, leading to a severely deficient form of abnormal frataxin and severe
phenotype. This suggests that the extremely low levels of mature frataxin produced from
W168R are no different than that from G130V, and that phenotypic differences related to
such mutations are most likely to reflect other abnormalities in the different mutants.
Additionally, we investigated if traditional therapies for increasing FXN levels
would be relevant to patients with W168R. Increasing precursor levels does not lead to
an increase in mature FXN81-210 levels. One explanation is that W168R slows down the
FXN processing rate in such that increased precursor FXN levels never get processed to
the mature form, possibly by blocking or inhibiting the second MPP cleavage site. In
summary, this data suggests that patients with W168R will require alternative
approaches to repair FXN processing from intermediate to mature form in order to
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increase FXN levels and treat the disorder in a disease-modifying manner. Furthermore,
functional studies will be required to ascertain the mechanism by which W168R affects
FXN function and leads to severe phenotype.
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Figure 3.1 W168R decrease FXN81–210 levels. Western blot of whole cell lysates collected
from HEK 293 cells transfected with FXNWT and FXNW168R. An anti-HA antibody was
used to detect exogenous FXN81–210 (15 kD) FXN81–210 levels after transfection.
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Figure 3.2 W168R does not impair FXN association with mitochondria. Confocal
microscopy images of HEK 293 cells cotransfected with mutant FXN constructs and
mito-GFP, fixed, and stained using a primary anti-HA antibody to detect exogenous FXN
only and secondary antibody Alexa Fluor 568 (FXN). DAPI was also used as a nuclear
stain.
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Figure 3.3 W168R enhances the association of FXN42–210 with MPP. Whole cell lysates
from transfected HEK 293 cells were immunoprecipitated with anti-MPP antibody and
immunoblotted with primary anti-HA antibody. Western blot was used to detect FXN
pulled down by anti- MPP. The Co-IP 19 kD blot represents immunoprecipitated FXN42210.
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Figure 3.4 W168R impairs processing from FXN42–210 to FXN81–210. Following transfection
of mutant constructs in HEK 293 cells, whole cell lysates were centrifuged to perform
subcellular fractionation of soluble mitochondria fraction and insoluble mitochondrial
pellet. FXN levels were detected by western blot using an anti-HA antibody.
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Figure 3.5 Increasing W168R FXN1–210 levels does not increase FXN81–210 levels.
Following transfection of HEK 293 cells with mutant FXN constructs, cells were treated
with 10 lmol/L MG132 proteasome inhibitor for 5 h followed by cell lysis. Exogenous
FXN1–210 (23 kD), FXN42–210 (19 kD), and FXN81–210 (15 kD) levels, before and
after treatment, were detected by western blot using a primary anti-HA antibody.
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Chapter 4: G130V Alleviates Mitochondria Dysfunction
4.1 Abstract
GAA trinucleotide repeats within intron 1 of the Frataxin (FXN) gene cause
decreased levels of protein and the slowly progressive, early onset Friedreich ataxia. In
typical FRDA, disease progression and age of onset correlates with the length of the
shortest GAA expansion. 2-3% of FRDA patients carry a GAA expansion on one FXN
allele, and a missense mutation on the other, and their FXN levels are generally lower
than typical FRDA patients. This would suggest that such patients have a very severe
phenotype; however, these patients can have a mild or severe clinical severity. FRDA
patients with the G130V mutation have significantly lower occurrence of cardiomyopathy,
scoliosis, and diabetes, and they surpass other point mutation-carrying subjects on
composite performance measures accounting for disease duration.
The mechanism by which G130V results in a milder FRDA phenotype is
unknown. In this chapter multiple features of mitochondrial function associated with
severe typical FRDA phenotype including enzymatic activity, energy metabolism, fusion
and ultrastructure were investigated, and compared to that of patients with milder
phenotype, carrying the G130V FXN missense mutation. Overall, primary fibroblasts
from G130V patients appear to have improved mitochondrial function compared to
typical FRDA patients, thus providing a rationale linking G130V functional capacity with
milder phenotype.
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4.2 Introduction
Usually presenting in the first two decades of life, Friedreich ataxia (FRDA)
causes slowly progressive ataxia, with dysarthria, spasticity in the lower limbs, scoliosis,
absence of lower limb reflexes, and loss of position and vibration sense.9,22,79 At present,
there is no cure or effective treatment. FRDA is a recessive neurodegenerative disease,
caused by decreased levels of the mitochondrial protein frataxin (FXN) resulting from
trinucleotide repeat expansions within intron 1 of the FXN gene. In typical FRDA, the
length of the shortest GAA expansion correlates with disease severity; longer GAA
expansions result in earlier onset and a faster progression.41,44,86 2-3% of FRDA patients
carry a GAA expansion on one FXN allele, and a missense mutation on the other, and
their FXN levels are generally lower than typical FRDA patients. The low FXN levels
suggest patients should have very severe phenotype. However, the phenotype cannot
be predicted based on FXN levels alone; as these patients can have a mild or severe
clinical course45 creating a unique platform to understand clinical and genetic
heterogeneity.
In a large cohort of FRDA subjects, those with the G130V mutation have
significantly lower levels of cardiomyopathy, scoliosis, and diabetes, and they perform
better on composite performance measures than other point mutation-carrying subjects
accounting for disease duration. Thus, they retain greater neurological function and
decreased disease severity at a similar length of disease duration.7,19,34,36,37,45,49,82,83,90,125
G130V does not impair FXN localization to mitochondria, but decreases mature FXN81–
210

levels, and is mostly present as the FXN42-210 intermediate form. Our hypothesis is
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that the G130V FXN42-210 intermediate form has sufficient functional capacity to carry out
the role of mature FXN81-210 for mitochondria function.
Many studies have implicated a role for FXN in iron metabolism, storage and
iron-sulfur (Fe-S) cluster biogenesis 23,30,38,60,68,71,80,94,95,110,123 A conserved primary Fe2+
binding site, with a dissociation constant within the micromolar range (3–55 µM),
involves residues of the acidic ridge localized within the first alpha helix 32,81,87,123. In
addition to Fe binding, FXN has been reported to interact with mitochondrial aconitase,
ferrochelatase and proteins of the mitochondrial Fe-S cluster machinery. 6,15,50,124 Fe is
essential for metabolic processes including oxygen transport, electron transport, DNA
synthesis, redox/non-redox reactions and other cell functions.42,75 In the central nervous
system (CNS) and brain, where energy requirements are high, ATP is in high demand
for synaptic transmission and distant axoplasmic transport, all of which involve Fe-S
enzymes of oxidative metabolism.31
Fe-S containing proteins play a crucial role in cellular respiration and ATP
production; therefore decreased activity has significant effects on mitochondria
function.15,30 FXN’s role in Fe-S cluster biogenesis makes it almost essential for
enzymatic activity of Fe-S containing aconitase and respiratory chain complexes.
Aconitase, unlike other Fe-S containing proteins, requires Fe-S clusters for activation
and conversion of citrate to isocitrate for Krebs cycle metabolism. Consequently,
decreased FXN results in decreased aconitase activity, both in cell culture models and in
vivo, and in heart tissues and biopsies of FRDA patients.65,70,85,97,102,119 Activities of Fe-S
containing proteins of the electron transport chain are also decreased in endomyocardial
biopsies of FRDA patients (Complexes I, II, and III),102 Primary FRDA patient fibroblasts
(Complexes I and II),77 and FRDA mouse models (Complexes I, II, and IV).33,76
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Mitochondrial iron accumulation is a hallmark of Fe-S deficiency. Friedreich
ataxia patients demonstrate iron deposits in cardiomyocytes, 65,70,85 iron metabolism
dysregulation in heart autopsies,70,102 mitochondrial iron overload85 and deficiency of FeS containing enzymes in the CNS.65 Although its role in disease pathophysiology is
uncertain, increased iron within mitochondria could lead to oxidative stress and
associated damage of dorsal root ganglion and spinal sensory neurons.11,23
Ferritin, a cytosolic protein, binds and stores intracellular iron to prevent the
formation of reactive oxygen species (ROS). Ferritin expression is induced by excess
iron and has been found at increased levels in some neurodegenerative diseases.21,35
Mitochondria require iron for heme and Fe-S cluster synthesis, but also generate large
amounts of hydrogen peroxide as by-products of respiratory activity.103 Mitochondrial
ferritin (FtMt) is a nuclear-encoded iron-sequestering protein that specifically localizes in
mitochondria. FtMt expression can reduce ROS levels, increase ATP levels and the
activity of mitochondrial Fe-S enzymes, positively effect cell viability, reduce cytosolic
and mitochondrial labile iron pools, rescue respiratory deficiency, reduce mitochondrial
iron accumulation, increase resistance to oxidants and protect cells from mitochondrial
DNA damage. 20,21,89 In FRDA patient fibroblasts, FtMt expression prevented the
formation of ROS and partially rescued the impaired activity of mitochondrial Fe-S
enzymes, caused by frataxin deficiency, suggesting FtMt involvement in controlling ROS
formation through mitochondrial iron regulation. Histological analysis of FRDA patient
samples suggested the role of FtMt in the formation of iron-rich structures,85 and
increased mitoferritin-2 mRNA has been observed in FRDA MCK mice.59
In this chapter, I investigate multiple features of mitochondrial dysfunction
associated with severe, FRDA phenotype including: FtMt levels, mitochondrial aconitase
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activity, Krebs cycle metabolic activity, and mitochondrial ultrastructure. Using primary
FRDA fibroblasts, we compared typical FRDA patients with G130V patients to
understand molecular mechanisms that may underlie milder phenotype in G130V
patients.
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4.3 Materials and Methods
4.3.1 Immunostaining
Primary fibroblasts from Control, Typical FRDA, and FRDA patients with G130V
mutation were fixed with 4% paraformaldehyde followed by treatment with blocking
buffer containing 5% normal goat serum, 3% Triton X-100, and 1% BSA. Primary
antibody to the mitochondrial ferritin epitope was added at a 1:100 dilution overnight.
Alexa Fluor 488 secondary antibody was added at a dilution of 1:100 and cells were
imaged by confocal microscopy.
4.3.2 Transfection for Live Imaging
Primary fibroblasts from Control, Typical FRDA, and FRDA patients with G130V
mutation were grown on coverslips and co-transfected via Lipofectamine 2000 reagent
with mito-DsRed2 and mito-PAGFP, 1ug each. Twenty four hours after transfection,
DsRed2 immunofluorescence was used to select single mitochondria regions of interest,
and UV 405 nm laser was used to activate mito-PAGFP for live imaging by confocal
microscopy with 5 seconds activation and 2 min time frame.
4.3.3 Aconitase Activity
Mitochondria were isolated from primary Control, typical FRDA, and G130V
patient fibroblasts. Aconitase activity was measured using the Aconitase Activity Assay
Kit (Sigma MAK051) and activity in typical FRDA and G130V fibroblasts was normalized
to control.
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4.3.4 Electron Microscopy
Control, typical FRDA, and G130V primary fibroblasts were washed with 1X PBS,
scraped from 10cm plates and gently centrifuged at 23 x g. The resulting pellet was fixed
with Paraformaldehyde/ Glutaraldehyde solution. Cells were embedded and sectioned in
1 micron sections and images were collected at 75,000x.
4.3.5 Isotope Labeling
Primary fibroblasts from Control, Typical FRDA, and FRDA patients with G130V
mutation were treated with 5mM [13C6]-Glucose for 3 hours. Cells were collected and
gently centrifuged at 23 x g. The resulting pellet was suspended in 10% TCA, and
prepared for LC-MS using solid phase extraction cleanup.
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4.4. Results
4.4.1 Decreased Mitochondrial Ferritin, Associated with Iron Overload in Typical FRDA,
is Absent in G130V Patient Fibroblasts
I first investigated mitochondrial ferritin (FtMt) levels, observed by
Immunohistochemistry, to compare patients with G130V with typical FRDA patients and
examine differences that may underlie phenotype severity. Decreased FtMt
immunoreactivity, compared to control, was present in typical FRDA patient fibroblasts,
as expected, but little to no change, compared to controls, was found in FRDA G130V
patient fibroblasts (Figure 4.1). This suggests the G130V mutation has the ability to
handle iron in a way that decreases or prevents mitochondria iron overload, thereby
contributing to milder phenotype.
4.4.2 Increased Mitochondrial Aconitase Activity in G130V FRDA Patient Fibroblasts
Compared to Typical FRDA
I next compared mitochondrial aconitase activity in fibroblasts from control,
typical FRDA patients, and FRDA patients with G130V. Mitochondrial aconitase activity
is significantly decreased in FRDA fibroblasts and significantly increased in FRDA
patients with G130V, compared to typical FRDA patients, and not significantly different
compared to controls (Figure 4.2). As FXNG130V is present predominantly as the FXN42-210
intermediate form, this supports functional capacity of FXN42-210 with G130V mutation to
participate in Fe-s cluster biogenesis in order to facilitate aconitase activity, compared to
typical FRDA patients.
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4.4.3 Increased TCA Metabolic Activity in G130V FRDA Patient Fibroblasts Compared to
Typical FRDA
Friedrich ataxia patients have dysregulated glucose metabolism leading to
increased palmitate-derived acyl-CoA thioesters.5,121 To further examine and compare
downstream mechanisms of mitochondria metabolism in control, typical FRDA, and
G130V patient fibroblasts, I utilized LC-MS-based isotopologue analysis to measure
incorporation of 13C-labeled carbon from Glucose to Succinyl Co A as a measure of
metabolic flux. Consistent with aconitase activity, Krebs cycle metabolic flux is
significantly decreased in FRDA fibroblasts compared to controls, while G130V
fibroblasts had increased activity compared to typical FRDA but decreased activity
compared to controls (Figure 4.3). This suggests that the hypothesized functional
capacity of G130V FXN42-210 to participate in Fe-S cluster biogenesis has downstream
effects on both aconitase and Krebs cycle activity as possible contributors to overall
improved mitochondria function and milder phenotypes, compared to typical FRDA.
4.4.4 G130V Patients Have Retained Mitochondrial Structure Compared to Typical
FRDA Patients
I further investigated if mitochondria dysfunction at the molecular level was
consistent with changes in mitochondrial ultrastructure by utilizing electron microscopy to
visualize mitochondrial ultrastructure in order to compare control, typical FRDA, and
G130V patient fibroblasts. Disrupted cristae formation and a lack of double membrane
structures was observed in typical FRDA patient fibroblasts, but maintained in G130V
patient fibroblasts (Figure 4.4A). A difference in glycogen content was also observed.
Glycogen levels in typical FRDA patient fibroblasts were significantly decreased
compared to both control and G130V, while glycogen content in G130V fibroblasts was
54

significantly increased compared to both control and typical FRDA fibroblasts (Figure
4.4B). This is consistent with evidence of dysregulated glucose metabolism present in
typical FRDA patients, and supports the improved Krebs cycle metabolic flux in G130V
fibroblast compared to typical FRDA fibroblasts.
4.4.5 Mitochondrial Fusion is Disrupted in Typical FRDA Patient Fibroblasts, but
Preserved in G130V
Mitochondrial fusion and fission are necessary events for maintaining
mitochondria under metabolic or environmental stress. I examined these events in both
a fixed-steady state and under dynamic real-time conditions. FRDA patient fibroblasts,
both typical and G130V, exhibit a pattern of mitochondrial fragmentation while control
fibroblasts maintain linear networks of mitochondria in a fixed-steady state (Figure 4.5).
However, while mitochondrial fragmentation is present in both typical and G130V patient
fibroblasts, real-time mitochondria fusion is impaired in typical FRDA patient fibroblasts,
but maintained in G130V patient fibroblasts (Figure 4.6). This suggests a possible role
for FXN G130V at the mitochondrial membrane to facilitate fusion and mitochondrial
maintenance as a contributor to milder phenotype.
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4.5 Discussion
In this chapter mitochondrial functions associated with severe phenotype in
typical FRDA were compared to that of patients with milder phenotype, carrying the
G130V FXN missense mutation. Primary fibroblasts from G130V patients have
increased FtMt immunoreactivity, mitochondrial aconitase activity and Krebs cycle
metabolic activity compared to typical FRDA primary fibroblasts. They also have retained
mitochondrial ultrastructure and preserved mitochondrial fusion, both of which were
disrupted in typical FRDA fibroblasts. Decreased FXN81-210 levels primarily cause
disease, but levels of this form of frataxin alone are not enough to predict disease
severity in heterozygous patients with point mutations, as patients with FXNG130V have
less FNX81-210 levels than typical FRDA patients. Wild Type FXN42-210 has functional
capacity in participating in Fe-S cluster biogenesis in vitro, and the present study
suggests that this FXN G130V form has sufficient functional capacity to retain FtMt
immunoreactivity and mitochondrial aconitase activity, glucose metabolic flux through
the Krebs cycle, mitochondrial ultrastructure, and preserve mitochondrial fusion, all of
which was decreased or impaired in typical FRDA patient fibroblasts.
There is greater systemic iron deficiency in typical FRDA patients121, compared
to G130V patients, as measured by serum ferritin levels. FXN deficiency leads to Fe-S
cluster biogenesis deficiency, further leading to mitochondrial iron overload. It has been
suggested that the decreased levels of FXN and increased iron within mitochondria lead
to oxidative stress and associated damage of dorsal root ganglion and spinal sensory
neurons.23 The protective effects of FtMt, when overexpressed in FXN-deficient cells,
included decreased mitochondrial iron overload, preserved mitochondrial DNA integrity,
and increased resistance on stress.20 The observed decrease in FtMt immunoreactivity
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in typical FRDA fibroblasts is indicative of mitochondrial iron overload, however
immunoreactivity in G130V patients fibroblasts was comparable to control suggesting
the G130V mutation provides FXN the ability to handle iron in a way that decreases or
prevents mitochondrial iron overload.
FXN plays a role in Fe-S cluster biogenesis, and aconitase is an Fe-S requiring
enzyme that participates in Krebs cycle isomerization of isocitrate to citrate.
Consequently, FXN deficiency leads to decreased activity of Fe-S containing enzymes.
Decreased aconitase activity has been demonstrated in FRDA patient samples but has
not been demonstrated in patients with G130V, or other missense mutations. The wild
type FXN42-210 intermediate form participates in Fe-S cluster biogenesis. The decreased
level of mitochondrial dysfunction in G130V primary fibroblasts indirectly confirms the
functionality of FXN42-210, and provides a functional rationale linking the G130V mutation
to a milder phenotype. G130V appears to offer additional functional capacity in the
FXN42-210 form that is otherwise not present to typical FRDA patients. The increased
aconitase activity, glucose metabolic flux through Krebs cycle, and mitochondrial fusion
all support functional capacity of FXN42-210 with G130V mutation to participate in Fe-s
cluster biogenesis and functional capacity at the mitochondrial membrane, leading to
healthier mitochondria and improved cell vitality, further contributing to milder phenotype
in these patients.
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Figure 4.1 Decreased mitochondrial ferritin in as absent in G130V patient fibroblasts.
Mitochondrial ferritin levels in primary human fibroblasts from control (CTRL), FRDA,
and G130V patients. A. Confocal microscopy images of patient fibroblasts (CTRL,
FRDA, and G130V) that were fixed and stained using primary anti-mitochondrial ferriting
antibody and secondary Alexa Fluor 488 antibody. DAPI was also used as a nuclear
stain. B. Quantification of mitochondrial ferritin immunoreactivity average intensity. (**) =
P < 0.05.

58

Figure 4.2 Increased Mitochondria Aconitase Activity in G130V FRDA patient fibroblasts.
Quantification of mitochondrial aconitase activity (millimunits/mL) from control, FRDA,
and G130V fibroblasts, normalized to control. (***) = P < 0.0005.
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Figure 4.3 Increased TCA metabolic activity in G130V FRDA patient fibroblasts.
Quantification of percent labeled [13C2}-Succinyl Co A following treatment of control,
typical FRDA, and G130V fibroblasts with [13C6]-Glucose for 3 hours, normalized to
control. (***) = P < 0.0005.
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Figure 4.4 G130V patients have retained mitochondria structure and increased
glycogen. A. Electron microscopy images of control, typical FRDA, and G130V
fibroblasts at 75,000x. B. Quantification glycogen content normalized to control. (***) = P
< 0.0005.
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Figure 4.5 Mitochondria fragmentation in FRDA patient fibroblasts. Confocal microscopy
images of patient fibroblasts (CTRL, FRDA, and G130V) transfected with mito-GFP and
fixed. DAPI was also used as a nuclear stain.
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Figure 4.6 Mitochondria fusion is preserved in G130V patient fibroblasts. Time-lapse
images of Control, typical FRDA, and G130V fibroblasts co-transfected with mitoDsRed2 and mito-PAGFP, activated for 5 seconds and imaged for 2 minutes.
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Supplemental Figure 4.1 Confocal microscopy images of control, typical FRDA, and
G230V fibroblasts cotransfected with WT FXN and mitoGFP, fixed, and stained using a
primary anti-HA antibody to detect exogenous FXN only and secondary antibody Alexa
Fluor 568. DAPI was also used as a nuclear stain.
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Chapter 5: Conclusions and Future Directions
5.1 Conclusions
In this thesis, I sought to understand the mechanism by which diseaseassociated missense mutation lead to mutation-selective phenotypes in FRDA by
investigating the effects of FRDA-associated missense mutations on FXN import into the
mitochondria and FXN processing, examining multiple features of mitochondria function
associated with severe typical FRDA phenotype and compared it to that of patients with
milder phenotype carrying the G130V FXN missense mutation.
The effects of FRDA-associated missense mutations on FXN import into the
mitochondria were first investigated by co-transfection of FXN variants containing a
C-terminal HA tag and mito-GFP in HEK 293 cells. With the exception of L106S, a
protein folding mutation that produces no protein, all variants: R165C, W155R, I154F,
G130V, and G137V co-localized with mito-GFP with a Pearson's correlation coefficient
greater than 0.98 and retained their mitochondria localization. FRDA patients carrying a
missense mutation generally have lower mature FXN81-210 levels than typical FRDA
patients. This is consistent with the decreased immunoreactivity in I154F, G130V, and
G137V by immunocytochemistry and western blot. To further investigate the decreased
FXN81–210 levels of particular FXN-mutant proteins, subcellular fractionation and
separation of the soluble and insoluble mitochondrial pellet was performed. R165C or
W155R resulted in FXN81–210 levels comparable to WT, while transfection of I154F or
G130V produced lower levels of FXN81–210 and increased levels of FXN42–210, suggesting
these FXN variants are not processed readily from FXN42–210 to the FXN81–210 form.
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Increased ratios of insoluble to soluble FXN42–210 were observed, suggesting these
proteins remain associated with the insoluble inner mitochondrial membrane rather than
being released into the soluble portion of the mitochondrion. To examine the mechanism
by which I154F and G130V impair FXN processing, co-immunoprecipitation was
performed to study the strength of the interaction between FXN and MPP. FXN42–
210

forms of I154F and G130V are more readily co-immunoprecipitated by anti-MPP than

the FXN42–210 form of WT, R165C, and W155R proteins, suggesting stronger attachment
between these variants and MPP. I next modeled the approach of traditional therapies to
increase FXN levels using the proteasome inhibitor MG132. While I154F and G130V
FXN1–210 and FXN42–210 levels increased, MG132 treatment did not increase FXN81–
210

levels suggesting that increasing FXN81–210 cannot be achieved with simple

overexpression of precursor FXN. Conclusively, the significance of these findings was
analyzed in patient-derived cells including Controls, Typical FRDA, and G130V patients,
and the processing of native FXN was examined by western blot. Indeed, the ratio of
FXN42–210 to FXN81–210 was increased in primary FRDA G130V patient fibroblasts, and
large globular structures, consistent with the increased insoluble FXN42–210 form detected
by western blot and overexpression studies, was observed. We then sought to establish
whether patients carrying missense point mutations displayed distinct clinical
abnormalities that could be related to the altered processing observed in vitro. Patients
carrying G130V mutations have significantly lower occurrence of cardiomyopathy,
scoliosis, and diabetes, the most severe components of the disease, compared to
patients with other mutations, and patients with an I154F mutation fell between the
phenotypic severity of G130V and other point mutations. We hypothesize that the
incompletely processed FXN42–210 carries some residual activity. This form is located in
the mitochondria, and others suggest that FXN42–210 can perform Fe-S cluster synthesis
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as well as participate in cysteine desulfurase activity as efficiently as FXN81–210. Thus,
the higher levels of FXN42–210 associated with G130V and I154F could lead to the milder
phenotype if this intermediate form is functional.
In addition to these disease-associated mutations, a patient who carries a novel
W168R missense mutation, and 1133 expanded GAA repeats on the opposite allele,
with extremely low levels of mature FXN81-210 levels and an especially severe phenotype
was presented. Based on the amino acid position 168, it is unlikely to alter FXN levels by
misfolding. In order to understand the mechanism by which W168R contributes to
severe phenotype, FXN import into the mitochondria, FXN processing, as well as FXN
interaction with MPP was investigated. W168R is expressed predominantly as the
intermediate FXN42-210 form, with little to no expression of the mature FXN81-210 form
consistent with patient samples, its localization to the mitochondria is not impaired, and
modeling traditional therapies to increase FXN1-210 levels does not increase mature FXN
levels. The G130V mutation, associated with milder phenotype, is also expressed
predominantly as the intermediate FXN42-210 form, with very low mature FXN81-210 form.
However, we believe the phenotypic differences likely to reflect mutation-specific
functional differences leading to mutation-specific phenotypes.
The mechanism by which G130V results in a milder FRDA phenotype is
unknown, thus I investigated multiple features of mitochondria function associated with
severe, typical FRDA phenotype including enzymatic activity, energy metabolism, fusion
and ultrastructure, and compared it to that of patients with milder phenotype, carrying the
G130V FXN missense mutation. Mitochondrial ferritin levels were first examined by
Immunohistochemistry. As expected, decreased mitochondria ferritin immunoreactivity
was present in typical FRDA patient fibroblasts, but little to no change, compared to
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controls, was found in G130V patient fibroblasts, suggesting the functional capacity of
G130V to handle iron in a way that decreases or prevents mitochondria iron overload.
Next, mitochondrial aconitase activity was compared with significantly decreased activity
in typical FRDA fibroblasts, and significantly increased activity in G130V fibroblasts
compared to typical FRDA patients and no significant difference compared to controls.
Downstream mechanisms of mitochondria metabolism were then examined by LC-MSbased isotopologue analysis to measure incorporation of 13C-labeled carbon from
Glucose to Succinyl Co A as a measure of metabolic flux. Consistent with aconitase
activity, Krebs cycle metabolic flux was significantly decreased in FRDA fibroblasts and
significantly increased in G130V patients compared to typical FRDA patients and no
significant difference compared to controls. This supports the hypothesized functional
capacity of G130V FXN42-210 to participate in Fe-S cluster biogenesis and suggest
G130V has downstream effects on both aconitase and Krebs cycle activity as possible
contributors to overall improved mitochondria function and milder phenotypes, compared
to typical FRDA. Subsequently, I investigated if the disrupted molecular mechanisms
were consistent with disrupted mitochondria structure by utilizing electron microscopy
and real-time imaging. Disrupted cristae formation and a lack of double membrane
structures was observed in typical FRDA patient fibroblasts, but maintained in G130V
patient fibroblasts. Decreased glycogen content was also observed in typical FRDA
fibroblasts consistent with evidence of dysregulated glucose metabolism in FRDA
patients. Mitochondrial fusion was examined under fixed-steady state and dynamic realtime conditions. FXN deficiency leads to mitochondria fragmentation in typical FRDA and
G130V fibroblasts, while control fibroblasts maintained linear networks of mitochondria in
a fixed-steady state. However, real-time mitochondria fusion is impaired in typical FRDA
patient fibroblasts, but maintained in G130V patient fibroblasts, suggesting a possible
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role for G130V at the mitochondria membrane to facilitate fusion and mitochondria
maintenance as a contributor to milder phenotype. Taken together, fibroblasts from
G130V patients overall appear to have improved mitochondria function compared to
typical FRDA patients, thus providing a rationale linking G130V functional capacity with
milder phenotype.
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5.2 Future directions
In this thesis I have identified mechanisms that underlie mutation-selective
phenotypes in FRDA patients with missense mutations. G130V, I154F, and W168R,
impair processing from intermediate FXN42–210 to mature FXN81–210 form, and increased
levels of the G130V FXN42–210 is associated with milder phenotypes, not only in
overexpression studies using mammalian systems, but also in primary fibroblasts from
FRDA patients. While others suggest that WT FXN42–210 can perform Fe-S cluster
synthesis as well as participate in cysteine desulfurase activity as efficiently as WT, this
is true also for the FXN42–210 form of W155R, a characterized dysfunctional mutation. The
W155R mutation does not impair processing and is predominantly expressed as mature
FXN81–210, therefore the severe phenotype could be associated with the dysfunctional
FXN81–210 in addition to GAA expansion on the other FXN allele. We believe the
incompletely processed FXN42–210 of G130V carries some residual activity, thus higher
levels of FXN42–210 associated could lead to the mild phenotype of patients if this
intermediate form is functional. Further experiments examining the functional capacity of
the endogenous FXN42–210 form missense mutation may help clarify these possibilities.
First, in vitro studies using site-directed mutagenesis of FXN42-210 constructs can be used
to establish if G130V and W168R can perform Fe-S cluster synthesis as well as
participate in cysteine desulfurase activity. If there were functional differences that
correlated with disease-associated phenotypes it would provide a functional mechanism
by which these mutations lead to the mutation-selective phenotypes.
I also showed that traditional therapies to increase precursor FXN1-210 levels
would not increase mature FXN81-210 levels. Patients with missense mutations carry the
mutation on one FXN allele and GAA expansion on the other. If this approach increased
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FXN81-210 levels of the GAA expanded FXN allele only by 20% and it was sufficient to
delay disease progression, then it would still be beneficial if the patient does not carry a
missense mutation characterized as dysfunctional. Furthermore, increasing G130V
FXN1-210 resulted in increased FXN42-210. If the G130V intermediate FXN42-210 form were
functional, it would also be an additional beneficial to the patients.
Patients with the G130V mutation have significantly lower occurrence of
cardiomyopathy, scoliosis, and diabetes, and they surpass other point mutation-carrying
subjects on composite performance measures accounting for disease duration. Finally,
multiple features of mitochondria dysfunction associated with severe FRDA phenotype
including: mitochondria ferritin levels, mitochondria aconitase activity, Krebs cycle
metabolic activity, and mitochondria ultrastructure using primary FRDA fibroblasts were
investigated. By comparing typical FRDA patients with G130V patients I sought to
assess molecular mechanisms that may underlie milder phenotype in G130V patients.
Many studies have implicated a role for FXN in iron metabolism, storage and
iron-sulfur cluster biogenesis. Mitochondrial iron accumulation is a hallmark of Fe-S
deficiency. Although its role is disease pathophysiology is uncertain, increased iron
within mitochondria could have downstream effects leading to oxidative stress and
associated damage of dorsal root ganglion and spinal sensory neurons. Mitochondria
ferritin expression can reduce reactive oxygen species (ROS) levels, increase ATP
levels and the activity of mitochondrial Fe-S enzymes, positively effect cell viability,
reduce cytosolic and mitochondrial labile iron pools, rescue respiratory deficiency,
reduce mitochondrial iron accumulation, increase resistance to oxidants and protect cells
from mitochondrial DNA damage. Decreased mitochondrial ferritin was observed, which
is associated with iron overload in typical FRDA fibroblasts. G130V patient fibroblasts
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maintained mitochondrial ferritin levels comparable to controls, suggesting that G130V
mutation has the ability to handle iron in a way that decreases or prevents mitochondria
iron overload. To examine this further, a colorimetric assay could be used to measure
iron levels from whole cell lysates and isolated mitochondria from patient fibroblasts. An
acidic buffer could be used to release iron in order to bind a chromagen resulting in a
colorimetric (593 nm) product, proportional to the iron present. A number of compounds
currently in the FRDA research pipeline are designed to decrease iron toxicity. This
approach could also be used to compare the effectiveness of these drugs in typical
FRDA and G130V patients, further supporting the hypothesized functional capacity of
G130V FXN42-210 to participate in Fe-S cluster synthesis and explain the overall improved
mitochondria function as a result of increased FXN function.
FXN has also been implicated in energy metabolism and ATP production. The
increased mitochondria aconitase enzymatic activity and Kreb cycle metabolic activity in
G130V fibroblasts further supports the hypothesized functional capacity of FXN42-210 with
G130V mutation to participate in Fe-S cluster biogenesis and lead to downstream effects
on metabolism and milder phenotype compared to typical FRDA. The impaired
mitochondria fusion under normal conditions in typical FRDA fibroblasts suggests FXN
deficiency leads to downstream effects functions both within the mitochondria and at the
membrane. Mitochondria number and electron chain complex activity is decreased as a
result of FXN deficiency in typical FRDA. FXN overexpression reverses mitochondria
fragmentation in both typical FRDA and G130V fibroblasts at steady state conditions
(Supplemental Figure 4.1). The question remains if increasing FXN levels will also
improve mitochondria enzymatic and metabolic activity, or if FRDA-associated FXN
deficiency over time leads to irreversible dysfunction. In order to assess if FXN has a
direct role in reversing fragmentation associated with FRDA pathology, fibroblasts could
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be treated with mitochondria fission inhibitor, such DRP1 inhibitor Mdivi-1, to see if the
reversed fragmentation is consistent. Following fragmentation reversal mitochondria
aconitase activity and [13C]-isotopologue analysis for Krebs cycle metabolic activity
could be measured to assess any improvement compared to typical FRDA baseline as
well as control and G130V. If there were no improvement that would suggest that other
therapies with mitochondria targets, such as PGC1 alpha up-regulators for mitochondria
biogenesis or Nrf2 activators, might be required. FXN deficiency is also associated with
decreased glucose incorporation and increased palmitate-derived acyl-CoA thioesters
formation in FRDA platelets compared with controls. Fibroblasts are limited as a model
system for studying metabolism, whereas platelets are metabolically active and analyterich, and used for biomarker studies to monitor new therapeutic approaches for the
treatment of FRDA. It would be interesting to assess these functional differences Krebs
cycle, lipid and fatty acid metabolism pathways in platelets from control, typical FRDA,
and G130V patients to assess correlation between metabolism and phenotype.
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